What's Going On With Tempus AI Shares Monday?

Comments
Loading...
Zinger Key Points

Tempus AI, Inc. TEM shares are moving higher on Monday. The company may be moving higher ahead of its 2024 fiscal-year fourth-quarter earnings report, which is scheduled to be released after the market closes.

What To Know: Analysts estimate a loss per share of 20 cents and revenue of $203.12 million, according to data from Benzinga Pro.

In its preliminary earnings report for the quarter, the company guided revenue of about $200 million. It also expects the trend of sequential improvement in adjusted EBITDA to continue.

“We concluded 2024 with continued strength in our core businesses, as genomics revenue is expected to grow at ~30% in Q4 and our data and services revenue is expected to grow at ~45%, such that we expect to deliver ~99% of our revenue guidance for 2024 and ~100% of our adjusted EBITDA guidance,” said Eric Lefkofsky, Founder and CEO of Tempus.

“Despite some softness in our CRO revenues, our core businesses gained momentum throughout the year.”

For the 2024 fiscal year third quarter, the company reported a loss of 25 cents per share, missing analysts’ estimate of a loss of 21 cents. In addition, Tempus reported revenue of $180.93 million, missing analysts’ estimate of $207.82 million.

See Also: Dollar Dips As Fed Holds Line, But JPMorgan Says Floor Is Near

TEM Price Action: At the time of writing, Tempus stock is trading 3.76% higher at $70.67, per data from Benzinga Pro.

Image: via Tempus

TEM Logo
TEMTempus AI Inc
$42.004.24%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
-
Growth
-
Quality
-
Value
13.77
Price Trend
Short
Medium
Long
Got Questions? Ask
How will Tempus AI's revenue growth impact its stock?
Which genomics companies may benefit from Tempus's growth?
What does Tempus's EBITDA guidance indicate for investors?
How might CRO revenue softness affect similar firms?
Will healthcare ETFs see increased interest with Tempus's performance?
What implications does analysts' loss estimate have for investor sentiment?
Which biotech stocks could be affected by Tempus's earnings report?
What trends in data and services revenue could signal for the industry?
How could Tempus's core business strength influence market competitors?
Are there investment opportunities in companies with similar revenue growth?
Market News and Data brought to you by Benzinga APIs

Posted In: